Study partners should be required in preclinical Alzheimer’s disease trials

Study partners should be required in preclinical Alzheimer’s disease trials

Abstract Background In an effort to intervene earlier in Alzheimer’s disease (AD), clinical trials are testing promising candidate therapies in preclinical disease. Preclinical AD trial participants are cognitively normal, functionally independent, and autonomous decision-makers. Yet, like AD dement...

Full description

Bibliographic Details
Main Authors: Joshua D. Grill, Jason Karlawish
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Alzheimer’s Research & Therapy
Subjects:
Preclinical Alzheimer’s disease
Informant
Clinical trial
Biomarker
Study partner
Online Access:http://link.springer.com/article/10.1186/s13195-017-0327-x

Internet

http://link.springer.com/article/10.1186/s13195-017-0327-x

Similar Items